Relating mode of action to clinical practice: Dopaminergic agents in Parkinson's disease

Parkinsonism and Related Disorders

Volumn 13, Issue 8, 2007, Pages 466-479

  Riederer, Peter ^a   Gerlach, Manfred ^a   Müller, Thomas ^b   Reichmann, Heinz ^c  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Dopamine agonists; Levodopa; Mode of action; Monoamine oxidase inhibitors

Indexed keywords

APOMORPHINE; BENSERAZIDE; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; LISURIDE; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; MONOAMINE OXIDASE INHIBITOR; PERGOLIDE; PLACEBO; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SELEGILINE; TOLCAPONE; TYRAMINE;

AREA UNDER THE CURVE; BINDING AFFINITY; CHEESE REACTION; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DOPAMINERGIC TRANSMISSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DYSKINESIA; FIBROSIS; FOOD DRUG INTERACTION; HALLUCINATION; HUMAN; HYPERTENSIVE CRISIS; LIVER TOXICITY; MONOTHERAPY; MOTOR DYSFUNCTION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PERICARDIAL DISEASE; PLEURAL FIBROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RETROPERITONEAL FIBROSIS; REVIEW; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; VALVULAR HEART DISEASE;

ANIMALS; DOPAMINE; DOPAMINE AGENTS; HUMANS; LEVODOPA; MODELS, BIOLOGICAL; PARKINSON DISEASE;

EID: 36049006160     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2007.06.015     Document Type: Review

References (154)

1. Ehringer H., and Hornykiewicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Klin Wochenschr 38 (1960) 1236-1239
2. Johnston T.H., and Brotchie J.M. Drugs in development for Parkinson's disease: an update. Curr Opin Invest Drugs 7 1 (2006) 25-32
3. Wu S.S., and Frucht S.J. Treatment of Parkinson's disease: what's on the horizon?. CNS Drugs 19 9 (2005) 723-743
4. Olanow C.W., Watts R.L., and Koller W.C. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 56 11 (Suppl 5) (2001) S1-S88
5. Olanow C.W., Agid Y., Mizuno Y., Albanese A., Bonucelli U., Damier P., et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 19 9 (2004) 997
6. Civelli O., Bunzow J.R., and Grandy D.K. Molecular diversity of the dopamine receptors. Annu Rev Pharmacol Toxicol 33 (1993) 281-307
7. Hurley M.J., and Jenner P. What has been learnt from study of dopamine receptors in Parkinson's disease?. Pharmacol Ther 111 3 (2006) 715-728
8. Thobois S., Vingerhoets F., Fraix V., Xie-Brustolin J., Mollion H., Costes N., et al. Role of dopaminergic treatment in dopamine receptor down-regulation in advanced Parkinson disease: a positron emission tomographic study. Arch Neurol 61 11 (2004) 1705-1709
9. Antonini A., Schwarz J., Oertel W.H., Pogarell O., and Leenders K.L. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride. Mov Disord 12 1 (1997) 33-38
10. Birkmayer W., and Hornykiewicz O. The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia. Wien Klin Wochenschr 73 (1961) 787-788
11. Hornykiewicz O. Physiologic, biochemical, and pathological backgrounds of levodopa and possibilities for the future. Neurology 20 12 (1970) 1-5
12. Cotzias G.C. Levodopa in the treatment of Parkinsonism. J Am Med Assos 218 13 (1971) 1903-1908
13. Birkmayer W., and Mentasti M. Further experimental studies on the catecholamine metabolism in extrapyramidal diseases (Parkinson and chorea syndromes). Arch Psychiatr Nervenkr 210 1 (1967) 29-35
14. Mercuri N.B., and Bernardi G. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?. Trends Pharmacol Sci 26 7 (2005) 341-344
15. Kim D.S., Szczypka M.S., and Palmiter R.D. Dopamine-deficient mice are hypersensitive to dopamine receptor agonists. J Neurosci 20 12 (2000) 4405-4413
16. Robinson S., Smith D.M., Mizumori S.J., and Palmiter R.D. Firing properties of dopamine neurons in freely moving dopamine-deficient mice: effects of dopamine receptor activation and anesthesia. Proc Natl Acad Sci USA 101 36 (2004) 13329-13334
17. Sotak B.N., Hnasko T.S., Robinson S., Kremer E.J., and Palmiter R.D. Dysregulation of dopamine signaling in the dorsal striatum inhibits feeding. Brain Res 1061 2 (2005) 88-96
18. Cannon C.M., Abdallah L., Tecott L.H., During M.J., and Palmiter R.D. Dysregulation of striatal dopamine signaling by amphetamine inhibits feeding by hungry mice. Neuron 44 3 (2004) 509-520
19. Lopez A., Munoz A., Guerra M.J., and Labandeira-Garcia J.L. Mechanisms of the effects of exogenous levodopa on the dopamine-denervated striatum. Neuroscience 103 3 (2001) 639-651
20. Venton B.J., Zhang H., Garris P.A., Phillips P.E., Sulzer D., and Wightman R.M. Real-time decoding of dopamine concentration changes in the caudate-putamen during tonic and phasic firing. J Neurochem 87 5 (2003) 1284-1295
21. Aubert I., Guigoni C., Hakansson K., Li Q., Dovero S., Barthe N., et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 57 1 (2005) 17-26
22. Vermeulen R.J., Drukarch B., Sahadat M.C., Goosen C., Wolters E.C., and Stoof J.C. The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeys. Mov Disord 9 6 (1994) 664-672
23. Jenner P. Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease. Curr Opin Neurol 16 Suppl 1 (2003) S3-S7
24. Kulisevsky J., Garcia-Sanchez C., Berthier M.L., Barbanoj M., Pascual-Sedano B., Gironell A., et al. Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients. Mov Disord 15 4 (2000) 613-626
25. Cools R., Stefanova E., Barker R.A., Robbins T.W., and Owen A.M. Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET. Brain 125 Pt 3 (2002) 584-594
26. Riekkinen M., Kejonen K., Jakala P., Soininen H., and Riekkinen Jr. P. Reduction of noradrenaline impairs attention and dopamine depletion slows responses in Parkinson's disease. Eur J Neurosci 10 4 (1998) 1429-1435
27. Federici M., Natoli S., Bernardi G., and Mercuri N.B. Dopamine selectively reduces GABA(B) transmission onto dopaminergic neurones by an unconventional presynaptic action. J Physiol 540 Pt 1 (2002) 119-128
28. Thorre K., Sarre S., Smolders I., Ebinger G., and Michotte Y. Dopaminergic regulation of serotonin release in the substantia nigra of the freely moving rat using microdialysis. Brain Res 796 1-2 (1998) 107-116
29. Centonze D., Gubellini P., Usiello A., Rossi S., Tscherter A., Bracci E., et al. Differential contribution of dopamine D2S and D2L receptors in the modulation of glutamate and GABA transmission in the striatum. Neuroscience 129 1 (2004) 157-166
30. Kreitzer A.C., and Malenka R.C. Dopamine modulation of state-dependent endocannabinoid release and long-term depression in the striatum. J Neurosci 25 45 (2005) 10537-10545
31. Agid Y. Levodopa: is toxicity a myth?. Neurology 50 4 (1998) 858-863
32. Michel P.P., and Hefti F. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res 26 (1990) 428-435
33. Steece-Collier K., Collier T.J., Sladek C.D., and Sladek Jr. J.R. Chronic levodopa impairs morphological development of grafted embryonic dopamine neurons. Exp Neurol 110 2 (1990) 201-208
34. Mytilineou C., Han S.-K., and Cohen G. Toxic and protective effects of L-DOPA on mesencephalic cell cultures. J Neurochem 61 (1993) 1470-1478
35. Mena M.A., Casarejos M.J., Carazo A., Paino C.L., and Garcia de Yebenes J. Glia protect fetal midbrain dopamine neurons in culture from L-DOPA toxicity through multiple mechanisms. J Neural Transm 104 4-5 (1997) 317-328
36. Mena M.A., Davila V., and Sulzer D. Neurotrophic effects of L-DOPA in postnatal midbrain dopamine neuron/cortical astrocyte cocultures. J Neurochem 69 4 (1997) 1398-1408
37. Mena M.A., Davila V., Bogaluvsky J., and Sulzer D. A synergistic neurotrophic response to l-dihydroxyphenylalanine and nerve growth factor. Mol Pharmacol 54 4 (1998) 678-686
38. Perry T.L., Yong V.W., Ito M., Foulks J.G., Wall R.A., Godin D.V., et al. Nigrostriatal dopaminergic neurons remain undamaged in rats gien high doses of L-DOPA and carbidopa chronically. J Neurochem 43 (1984) 990-993
39. Murer M.G., Dziewczapolski G., Menalled L.B., Garcia M.C., Agid Y., Gershanik O., et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 43 5 (1998) 561-575
40. Reches A., Fahn S., and Bhawan J. Chronic dopa feeding of mice. Neurology 32 6 (1982) 684-685
41. Lyras L., Zeng B.Y., McKenzie G., Pearce R.K., Halliwell B., and Jenner P. Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys. J Neural Transm 109 1 (2002) 53-67
42. Pearce R.K., Heikkila M., Linden I.B., and Jenner P. L-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations. Psychopharmacology (Berlin) 156 4 (2001) 402-409
43. Blunt S.B., Jenner P., and Marsden C.D. Suppressive effect of l-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov Disord 8 2 (1993) 129-133
44. Datla K.P., Blunt S.B., and Dexter D.T. Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions. Mov Disord 16 3 (2001) 424-434
45. Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A., et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 351 24 (2004) 2498-2508
46. Gnanalingham K.K., and Robertson R.G. The effects of chronic continuous dopamine receptors and dopamine uptake sites in the 6-hydroxydopamine lesioned rat-an autoradiographic study. Brain Res 640 1-2 (1994) 185-194
47. Gordon I., Weizman R., and Rehavi M. Modulatory effect of agents active in the presynaptic dopaminergic system on the striatal dopamine transporter. Eur J Pharmacol 298 1 (1996) 27-30
48. Marsden C.D., and Parkes J.D. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1 8007 (1977) 345-349
49. Olanow C.W., Obeso J.A., and Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 5 8 (2006) 677-687
50. Obeso J.A., Rodriguez-Oroz M., Marin C., Alonso F., Zamarbide I., Lanciego J.L., et al. The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology 62 1 (Suppl. 1) (2004) S17-S30
51. Furlanut M., Furlanut Jr. M., and Benetello P. Monitoring of L-dopa concentrations in Parkinson's disease. Pharmacol Res 43 5 (2001) 423-427
52. Nakao N., Shintani-Mizushima A., Kakishita K., and Itakura T. The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease. Exp Neurol 188 1 (2004) 65-73
53. Fabbrini G., Mouradian M.M., Juncos J.L., Schlegel J., Mohr E., and Chase T.N. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I. Ann Neurol 24 3 (1988) 366-371
54. Spencer S.E., and Wooten G.F. Altered pharmacokinetics of L-dopa metabolism in rat striatum deprived of dopaminergic innervation. Neurology 34 8 (1984) 1105-1108
55. Olanow C.W., and Obeso J.A. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors. Neurology 55 11 (Suppl. 4) (2000) S72-S77 discussion S8-81
56. Olanow W., Schapira A.H., and Rascol O. Continuous dopamine-receptor stimulation in early Parkinson's disease. Trends Neurosci 23 10 Suppl (2000) S117-S126
57. Abercrombie E.D., Bonatz A.E., and Zigmond M.J. Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res 525 1 (1990) 36-44
58. de la Fuente-Fernandez R., Lu J.Q., Sossi V., Jivan S., Schulzer M., Holden J.E., et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann Neurol 49 3 (2001) 298-303
59. Calon F., Grondin R., Morissette M., Goulet M., Blanchet P.J., Di Paolo T., et al. Molecular basis of levodopa-induced dyskinesias. Ann Neurol 47 4 (Suppl 1) (2000) S70-S78
60. Calon F., Birdi S., Rajput A.H., Hornykiewicz O., Bedard P.J., and Di Paolo T. Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias. J Neuropathol Exp Neurol 61 2 (2002) 186-196
61. Morissette M., Goulet M., Soghomonian J.J., Blanchet P.J., Calon F., Bedard P.J., et al. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy. Brain Res Mol Brain Res 49 1-2 (1997) 55-62
62. Cenci M.A., Tranberg A., Andersson M., and Hilbertson A. Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment. Neuroscience 94 2 (1999) 515-527
63. Graybiel A.M., Canales J.J., and Capper-Loup C. Levodopa-induced dyskinesias and dopamine-dependent stereotypies: a new hypothesis. Trends Neurosci 23 10 Suppl (2000) S71-S77
64. Canales J.J., and Graybiel A.M. Patterns of gene expression and behavior induced by chronic dopamine treatments. Ann Neurol 47 4 Suppl 1 (2000) S53-S59
65. Obeso J.A., Rodriguez-Oroz M.C., Rodriguez M., DeLong M.R., and Olanow C.W. Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model. Ann Neurol 47 4 (Suppl. 1) (2000) S22-S32 discussion S-4
66. Gerlach M., Reichmann H., and Riederer P. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 20 5 (2005) 643
67. Maratos E.C., Jackson M.J., Pearce R.K., Cannizzaro C., and Jenner P. Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus). Exp Neurol 179 1 (2003) 90-102
68. Rinne U.K. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease. Neurology 39 3 (1989) 336-339
69. Stocchi F., Vacca L., Ruggieri S., and Olanow C.W. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 62 6 (2005) 905-910
70. Cedarbaum J.M., Silvestri M., and Kutt H. Sustained enteral administration of levodopa increases and interrupted infusion decreases levodopa dose requirements. Neurology 40 6 (1990) 995-997
71. Cedarbaum J.M. The promise and limitations of controlled-release oral levodopa administration. Clin Neuropharmacol 12 3 (1989) 147-166
72. Koller W.C., Hutton J.T., Tolosa E., and Capilldeo R. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology 53 5 (1999) 1012-1019
73. Dupont E., Andersen A., Boas J., Boisen E., Borgmann R., Helgetveit A.C., et al. Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurol Scand 93 1 (1996) 14-20
74. Rascol O., Goetz C., Koller W., Poewe W., and Sampaio C. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 359 9317 (2002) 1589-1598
75. Silver D.E. Clinical experience with the novel levodopa formulation entacapone+levodopa+carbidopa (Stalevo). Expert Rev Neurother 4 4 (2004) 589-599
76. Gordin A., Kaakkola S., and Teravainen H. Clinical advantages of COMT inhibition with entacapone-a review. J Neural Transm 111 10-11 (2004) 1343-1363
77. Gordin A. The efficacy and safety of COMT inhibition in clinical trials in Parkinson's disease. Mov Disord 11 Suppl 1 (1996) 267
78. Schrag A. Entacapone in the treatment of Parkinson's disease. Lancet Neurol 4 6 (2005) 366-370
79. Ruottinen H.M., and Rinne U.K. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clin Neuropharmacol 19 4 (1996) 283-296
80. Nutt J.G. Effect of COMT inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 55 11 (Suppl 4) (2000) S33-S37 discussion S8-41
81. Gerlach M., van den Buuse M., Blaha C., Bremen D., and Riederer P. Entacapone increases and prolongs the central effects of l-DOPA in the 6-hydroxydopamine-lesioned rat. Naunyn Schmiedebergs Arch Pharmacol 370 5 (2004) 388-394
82. Muller T., Erdmann C., Muhlack S., Bremen D., Przuntek H., and Woitalla D. Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels. Mov Disord 21 3 (2006) 332-336
83. Brooks D.J., and Sagar H. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry 74 8 (2003) 1071-1079
84. Rinne U.K., Larsen J.P., Siden A., and Worm-Petersen J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 51 5 (1998) 1309-1314
85. Poewe W.H., Deuschl G., Gordin A., Kultalahti E.R., and Leinonen M. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 105 4 (2002) 245-255
86. Smith L.A., Jackson M.J., Al-Barghouthy G., Rose S., Kuoppamaki M., Olanow W., et al. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Mov Disord 20 3 (2004) 306-314
87. Nissinen H., Kuoppamaki M., and Leinonen M. Early initiation of entacapone leads to superior 5-year efficacy compared to delayed initiation in Parkinson's disease patients receiving traditional levodopa/DDCI therapy. Mov Disord 21 Suppl 13 (2006) S111
88. Pahwa R., Factor S.A., Lyons K.E., Ondo W.G., Gronseth G., Bronte-Stewart H., et al. Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2006)
89. Youdim M.B., Edmondson D., and Tipton K.F. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7 4 (2006) 295-309
90. Collins G.G., Sandler M., Williams E.D., and Youdim M.B. Multiple forms of human brain mitochondrial monoamine oxidase. Nature 225 5235 (1970) 817-820
91. O'Carroll A.M., Fowler C.J., Phillips J.P., Tobbia I., and Tipton K.F. The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions. Naunyn Schmiedebergs Arch Pharmacol 322 3 (1983) 198-202
92. Riederer P., and Youdim M.B. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. J Neurochem 46 5 (1986) 1359-1365
93. Youdim M.B., and Riederer P.F. A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease. Neurology 63 7 (Suppl 2) (2004) S32-S35
94. Ives N.J., Stowe R.L., Marro J., Counsell C., Macleod A., Clarke C.E., et al. Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients. Br Med J 329 7466 (2004) 593
95. Palhagen S., Heinonen E., Hagglund J., Kaugesaar T., Maki-Ikola O., and Palm R. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 66 8 (2006) 1200-1206
96. Parkinson S.G. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol 39 (1996) 29-36
97. Group P.S. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 59 12 (2002) 1937-1943
98. Heikkila R.E., Manzino L., Cabbat F.S., and Duvoisin R.C. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311 5985 (1984) 467-469
99. Koutsilieri E., O'Callaghan J.F., Chen T.S., Riederer P., and Rausch W.D. Selegiline enhances survival and neurite outgrowth of MPP(+)-treated dopaminergic neurons. Eur J Pharmacol 269 3 (1994) R3-R4
100. Mytilineou C., Radcliffe P., Leonardi E.K., Werner P., and Olanow C.W. L-deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro. J Neurochem 68 1 (1997) 33-39
101. Tatton W.G., Chalmers-Redman R.M., Ju W.J., Mammen M., Carlile G.W., Pong A.W., et al. Propargylamines induce antiapoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells. J Pharmacol Exp Ther 301 2 (2002) 753-764
102. Youdim M.B., Wadia A., Tatton W., and Weinstock M. The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann NY Acad Sci 939 (2001) 450-458
103. Akao Y., Maruyama W., Yi H., Shamoto-Nagai M., Youdim M.B., and Naoi M. An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett 326 2 (2002) 105-108
104. Youdim M.B., and Weinstock M. Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. Cell Mol Neurobiol 21 6 (2001) 555-573
105. Birkmayer W., Knoll J., Riederer P., Youdim M.B., Hars V., and Marton J. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J Neural Transm 64 2 (1985) 113-127
106. Tetrud J.W., and Langston J.W. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 245 4917 (1989) 519-522
107. Olanow C.W., Hauser R.A., Gauger L., Malapira T., Koller W., Hubble J., et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 38 5 (1995) 771-777
108. Przuntek H., Conrad B., Dichgans J., Kraus P.H., Krauseneck P., Pergande G., et al. SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa. Eur J Neurol 6 2 (1999) 141-150
109. Schulzer M., Mak E., and Calne D.B. The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic. Ann Neurol 32 6 (1992) 795-798
110. Fowler J.S., Volkow N.D., Logan J., Wang G.J., MacGregor R.R., Schyler D., et al. Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal. Synapse 18 2 (1994) 86-93
111. Youdim M.B., and Tipton K.F. Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease. Parkinsonism Relat Disord 8 4 (2002) 247-253
112. Clarke A., Brewer F., Johnson E.S., Mallard N., Hartig F., Taylor S., et al. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J Neural Transm 110 11 (2003) 1241-1255
113. Riederer P., and Lachenmayer L. Selegiline's neuroprotective capacity revisited. J Neural Transm 110 11 (2003) 1273-1278
114. Lees A.J. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Br Med J 311 (1995) 1602-1607
115. Hauser R., Lew M., Hurtig H., Ondo W., and Wojcieszek J. Early treatment with rasagiline is more beneficial than delayed treatment start in the long-term management of Parkinson's disease. Mov Disord 20 Suppl. 10 (2005) S75
116. Schapira A.H., and Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal?. Ann Neurol 59 3 (2006) 559-562
117. Suchowersky O., Gronseth G., Perlmutter J., Reich S., Zesiewicz T., and Weiner W.J. Practice parameter: neuroprotective strategies and alternative Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66 7 (2006) 976-982
118. PSG. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. J Am Med Assn 284 15 (2000) 1931-1938
119. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., and Lang A.E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342 20 (2000) 1484-1491
120. Bracco F., Battaglia A., Chouza C., Dupont E., Gershanik O., Marti Masso J.F., et al. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs 18 11 (2004) 733-746
121. Oertel W.H., Wolters E., Sampaio C., Gimenez-Roldan S., Bergamasco B., Dujardin M., et al. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study. Mov Disord 21 3 (2006) 343-353
122. Foley P., Gerlach M., Double K.L., and Riederer P. Dopamine receptor agonists in the therapy of Parkinson's disease. J Neural Transm 111 10-11 (2004) 1375-1446
123. Bonuccelli U., and Pavese N. Dopamine agonists in the treatment of Parkinson's disease. Expert Rev Neurother 6 1 (2006) 81-89
124. Gerlach M., Double K., Arzberger T., Leblhuber F., Tatschner T., and Riederer P. Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J Neural Transm 110 10 (2003) 1119-1127
125. Korczyn A.D., Brunt E.R., Larsen J.P., Nagy Z., Poewe W.H., and Ruggieri S. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group. Neurology 53 2 (1999) 364-370
126. Hanna P.A., Ratkos L., Ondo W.G., and Jankovic J. Switching from pergolide to pramipexole in patients with Parkinson's disease. J Neural Transm 108 1 (2001) 63-70
127. Horowski R., Jahnichen S., and Pertz H.H. Fibrotic valvular heart disease is not related to chemical class but to biological function: 5-HT2B receptor activation plays crucial role. Mov Disord 19 12 (2004) 1523-1524
128. Muller T., and Fritze J. Fibrosis associated with dopamine agonist therapy in Parkinson's disease. Clin Neuropharmacol 26 3 (2003) 109-111
129. Reichmann H., Brecht M.H., Koster J., Kraus P.H., and Lemke M.R. Pramipexole in routine clinical practice: a prospective observational trial in Parkinson's disease. CNS Drugs 17 13 (2003) 965-973
130. Lemke M.R., Brecht H.M., Koester J., Kraus P.H., and Reichmann H. Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole. J Neuropsychiatry Clin Neurosci 17 2 (2005) 214-220
131. Rinne U.K., Bracco F., Chouza C., Dupont E., Gershanik O., Marti Masso J.F., et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 55 Suppl. 1 (1998) 23-30
132. Oertel W.H., Wolters E., Sampaio C., Gimenez-Roldan S., Bergamasco B., Dujardin M., et al. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: the PELMOPET study. Mov Disord 21 3 (2005) 343-353
133. Weintraub D., Siderowf A.D., Potenza M.N., Goveas J., Morales K.H., Duda J.E., et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 63 7 (2006) 969-973
134. Driver-Dunckley E., Samanta J., and Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 61 3 (2003) 422-423
135. Dodd M.L., Klos K.J., Bower J.H., Geda Y.E., Josephs K.A., and Ahlskog J.E. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 62 9 (2005) 1377-1381
136. Klos K.J., Bower J.H., Josephs K.A., Matsumoto J.Y., and Ahlskog J.E. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 11 6 (2005) 381-386
137. Giovannoni G., O'Sullivan J.D., Turner K., Manson A.J., and Lees A.J. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 68 4 (2000) 423-428
138. Korner Y., Meindorfner C., Moller J.C., Stiasny-Kolster K., Haja D., Cassel W., et al. Predictors of sudden onset of sleep in Parkinson's disease. Mov Disord 19 11 (2004) 1298-1305
139. Comella C. Sleep episodes in Parkinson's disease: more questions remain. Sleep Med 4 4 (2003) 267-268
140. Frucht S. Sudden-onset sleep in Parkinson disease. J Am Med Assos 287 16 (2002) 2076 author reply -7
141. Cantor C.R., and Stern M.B. Dopamine agonists and sleep in Parkinson's disease. Neurology 58 90001 (2002) 71S-78S
142. Frucht S., Rogers J.D., Greene P.E., Gordon M.F., and Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 52 9 (1999) 1908
143. Rinne U.K., Bracco F., Chouza C., Dupont E., Gershanik O., Marti Masso J.F., et al. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group. Neurology 48 2 (1997) 363-368
144. Korczyn A., DeDeyn P., Rascol O., and Lang A. Incidence of dyskinesia in a 10-year follow-up of patients with early parkinson's disease (PD) initially receiving ropinirole compared with L-dopa. Neurology 64 Suppl 1 (2005) A396 S47
145. Holloway R.G., Shoulson I., Fahn S., Kieburtz K., Lang A., Marek K., et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61 7 (2004) 1044-1053
146. Lees A.J., Katzenschlager R., Head J., and Ben-Shlomo Y. Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial. Neurology 57 9 (2001) 1687-1694
147. PSG. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol 60 12 (2003) 1721-1728
148. Miyasaki J.M., Martin W., Suchowersky O., Weiner W.J., and Lang A.E. Practice parameter: Initiation of treatment for Parkinson's disease: an evidence-based review: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 58 1 (2002) 11-17
149. Przuntek H., Welzel D., Gerlach M., Blumner E., Danielczyk W., Kaiser H.J., et al. Early institution of bromocriptine in Parkinson's disease inhibits the PRADO study. J Neural Transm 103 6 (1996) 699-715
150. Lang A. The develoment of dyskinesias in Parkinson's-disease patients receiving ropinirole and given supplemental L-dopa. Neurology 56 Suppl 3 (2002) A82
151. Kieburtz K., Romer M., McDermott M., and Kamp C. Impact of pramipexole on the onset of levodopa related dyskinesia (CALM-PD). Mov Disord (2006)
152. Nyholm D., Lennernas H., Gomes-Trolin C., and Aquilonius S.M. Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson's disease on individual drug combinations. Clin Neuropharmacol 25 2 (2002) 89-96
153. Rascol O., Brooks D.J., Melamed E., Oertel W., Poewe W., Stocchi F., et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365 9463 (2005) 947-954
154. PSG. The COMT inhibitor entacapone improves Parkinsonian features in fluctuating patients. Mov Disord 11 Suppl 1 (1996) 268